Coronavirus Infection, Inflammatory Bowel Diseases
Conditions
Brief summary
To find out what adaptations have been made by Inflammatory bowel disease physicians and patients in relation to therapies in flaring IBD patients during severe acute respiratory syndrome 2-COV and what the impact of these is on IBD patients with no symptomatic COVID-19 and in suspected/confirmed COVID-19. Also whether there any IBD related factors impacting the outcome of patients with COVID-19 symptoms or COVID-19 disease
Detailed description
An observational, retrospective, case-controlled study to determine the status of IBD during development of COVID-19 symptoms/positive COVID-19. The aim is to describe the adaptations in therapies for active IBD during SARS COV 2 in patients with active IBD and positive or negative COVID-19 symptoms. It will evaluate IBD outcomes following development of COVID-19 symptoms / positive COVID-19 and determine any predictors of outcomes in IBD patients with COVID-19 symptoms / positive COVID-19 as well as determine the impact on IBD outcomes resulting from adaptations to treatments during COVID-19
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
* Patients with IBD +/- flare +/- COVID 19 positivity
Exclusion criteria
* Patients below 16 * Patient with inactive IBD
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Flare of IBD needing change in therapy or surgery | 3 months |
Countries
United Kingdom